Cargando…

No SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected Before the 2020 Pandemic

The 2020 SARS-CoV-2 pandemic is caused by a zoonotic coronavirus transmitted to humans, similar to earlier events. Whether the other, seasonally circulating coronaviruses induce cross-reactive, potentially even cross-neutralizing, antibodies to the new species in humans is unclear. The question is p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schwaiger, Julia, Karbiener, Michael, Aberham, Claudia, Farcet, Maria R, Kreil, Thomas R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Major Articles and Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7546122/ https://www.ncbi.nlm.nih.gov/pubmed/32941626 http://dx.doi.org/10.1093/infdis/jiaa593

Ejemplares similares

Rapidly Increasing Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Intravenous Immunoglobulins Produced From Plasma Collected During the 2020 Pandemic( )
por: Farcet, Maria R, et al.
Publicado: (2021)

Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization by Immunoglobulin Preparations Manufactured From Plasma Collected in the United States and Europe( )
por: Farcet, Maria R, et al.
Publicado: (2022)

Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins
por: Karbiener, Michael, et al.
Publicado: (2021)

Function matters: Coronavirus cross-binding antibodies do not cross-neutralize
por: Farcet, Maria R., et al.
Publicado: (2022)

Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis
por: Lackner, Cornelia, et al.
Publicado: (2022)

Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines
por: Karbiener, Michael, et al.
Publicado: (2022)

Orthopox viruses and the safety margins of solvent‐detergent treated plasma‐derived medicinal products
por: Kindermann, Johanna, et al.
Publicado: (2022)

Antibody‐enhanced hepatitis E virus nanofiltration during the manufacture of human immunoglobulin
por: Kapsch, Anna‐Maria, et al.
Publicado: (2020)

Characterization of 100 sequential SARS‐CoV‐2 convalescent plasma donations
por: Jungbauer, Christof, et al.
Publicado: (2020)

Detergent-Mediated Virus Inactivation in Biotechnological Matrices: More than Just CMC
por: Farcet, Jean-Baptiste, et al.
Publicado: (2023)

Longitudinal analysis of SARS‐CoV‐2 antibodies in 8000 U.S. first‐time convalescent plasma donations
por: Karbiener, Michael, et al.
Publicado: (2021)

Synthesis of “Nereid,” a new phenol‐free detergent to replace Triton X‐100 in virus inactivation
por: Farcet, Jean‐Baptiste, et al.
Publicado: (2020)

Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2
por: Klingler, Jéromine, et al.
Publicado: (2020)

Plasma and Mucosal Immunoglobulin M, Immunoglobulin A, and Immunoglobulin G Responses to the Vibrio cholerae O1 Protein Immunome in Adults With Cholera in Bangladesh
por: Charles, Richelle C., et al.
Publicado: (2017)

Early Appearance of Neutralizing Immunoglobulin G3 Antibodies Is Associated With Chikungunya Virus Clearance and Long-term Clinical Protection
por: Kam, Yiu-Wing, et al.
Publicado: (2012)

Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Hyperimmune Immunoglobulin Demonstrates Potent Neutralization and Antibody-Dependent Cellular Cytotoxicity and Phagocytosis Through N and S Proteins
por: Díez, José María, et al.
Publicado: (2021)

Commercial Immunoglobulin Products Contain Neutralizing Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 Spike Protein
por: Upasani, Vinit, et al.
Publicado: (2023)

Medicinal Immunoglobulin G Products (2020) Show High Infectivity Neutralizing Activity Against Seasonal Influenza Virus Strains Selected for Future Vaccines (2020–2022)
por: Díez, José María, et al.
Publicado: (2022)

The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis
por: Mair-Jenkins, John, et al.
Publicado: (2015)

A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
por: Maor, Yasmin, et al.
Publicado: (2023)

Effects of Severe Acute Respiratory Syndrome Coronavirus 2 Strain Variation on Virus Neutralization Titers: Therapeutic Use of Convalescent Plasma
por: Nguyen, Dung, et al.
Publicado: (2021)

Schistosoma mansoni Infection in Preschool-Aged Children: Development of Immunoglobulin E and Immunoglobulin G(4) Responses to Parasite Allergen-Like Proteins
por: Pinot de Moira, Angela, et al.
Publicado: (2013)

Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma
por: Girardin, Roxie C, et al.
Publicado: (2021)

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice
por: Hohenadl, Christine, et al.
Publicado: (2014)

Isoagglutinin‐reduced immunoglobulin retains efficacy in mouse models of immune thrombocytopenia and rheumatoid arthritis and is less likely to cause intravenous immunoglobulin–associated hemolysis
por: Cen, Selena Y., et al.
Publicado: (2019)

Intramuscular vs Intravenous SARS-CoV-2 Neutralizing Antibody Sotrovimab for Treatment of COVID-19 (COMET-TAIL): A Randomized Noninferiority Clinical Trial
por: Shapiro, Adrienne E, et al.
Publicado: (2023)

COVID-19 mRNA Vaccination Generates Greater Immunoglobulin G Levels in Women Compared to Men
por: Demonbreun, Alexis R, et al.
Publicado: (2021)

Plasma Biomarkers of Human Immunodeficiency Virus–Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy
por: Kroeze, Stefanie, et al.
Publicado: (2019)

The clinical response of West Nile virus neuroinvasive disease to intravenous immunoglobulin therapy
por: Shimoni, Zvi, et al.
Publicado: (2012)

Neutralizing activities against seasonal influenza viruses in human intravenous immunoglobulin
por: Onodera, Hiroyuki, et al.
Publicado: (2017)

Augmented Zika and Dengue Neutralizing Antibodies Are Associated With Guillain-Barré Syndrome
por: Lynch, Rebecca M, et al.
Publicado: (2019)

Durability of Viral Neutralization in Asymptomatic Coronavirus Disease 2019 for at Least 60 Days
por: Haymond, Amanda, et al.
Publicado: (2021)

Immunoglobulin Attenuates Streptokinase-Mediated Virulence inStreptococcus dysgalactiae Subspeciesequisimilis Necrotizing Fasciitis
por: Andreoni, Federica, et al.
Publicado: (2018)

Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H
por: Fan, Yongfeng, et al.
Publicado: (2016)

Sequential Intravenous-Oral Therapy for Pediatric Streptococcus anginosus Intracranial Infections
por: Dodson, Daniel S, et al.
Publicado: (2022)

The Epidemiology and Clinical Features of Non-Keratitis Acanthamoeba Infections in the United States, 1956–2020
por: Haston, Julia C, et al.
Publicado: (2023)

Effect of D614G Spike Variant on Immunoglobulin G, M, or A Spike Seroassay Performance
por: Klumpp-Thomas, Carleen, et al.
Publicado: (2020)

Breast Milk Prefusion F Immunoglobulin G as a Correlate of Protection Against Respiratory Syncytial Virus Acute Respiratory Illness
por: Mazur, Natalie I, et al.
Publicado: (2019)

Serum Immunoglobulin A Cross-Strain Blockade of Human Noroviruses
por: Lindesmith, Lisa C., et al.
Publicado: (2015)

Pediatric Hereditary Neuralgic Amyotrophy: Successful Treatment With Intravenous Immunoglobulin and Insights Into SEPT9 Pathogenesis
por: Chuk, Raymond, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_96mklb1mbmoir9si164aotehd7